(Q34030515)

30 July 2017

1 reference

title

Prostate cancer: 9. Treatment of advanced disease (English)

1 reference

30 July 2017

1 reference

Gleave ME

1

1 reference

30 July 2017

Bruchovsky N

series ordinal

2

1 reference

30 July 2017

Moore MJ

series ordinal

3

1 reference

30 July 2017

Venner P

series ordinal

4

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 January 1999

1 reference

Canadian Medical Association Journal

30 July 2017

published in

1 reference

30 July 2017

volume

160

1 reference

30 July 2017

issue

2

1 reference

30 July 2017

page(s)

225-232

1 reference

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate carcinoma. Analysis of time to progression. CASODEX Combination Study Group

30 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

Suramin, an active drug for prostate cancer: interim observations in a phase I trial

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

Characterization of two cis-acting DNA elements involved in the androgen regulation of the probasin gene

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

Estrogens in the treatment of prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

The conversion of testosterone to 5-alpha-androstan-17-beta-ol-3-one by rat prostate in vivo and in vitro.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

28 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

Luteinizing hormone-releasing hormone agonists in prostate cancer. Elimination of flare reaction by pretreatment with cyproterone acetate and low-dose diethylstilbestrol

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

Use of palliative end points to evaluate the effects of mitoxantrone and low-dose prednisone in patients with hormonally resistant prostate cancer.

29 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1229995

The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer

29 October 2018

1 reference

12 December 2020

Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer

1 reference

12 December 2020

Bilateral Adrenalectomy in Prostatic Cancer: Clinical Features and Urinary Excretion of 17-Ketosteroids and Estrogen

1 reference

12 December 2020

Chemotherapy programs of the National Prostatic Cancer Project (NPCP).

1 reference

12 December 2020

Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer

1 reference

12 December 2020

Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects

1 reference

12 December 2020

Orchiectomy versus goserelin and flutamide in the treatment of newly diagnosed metastatic prostate cancer. Analysis of the criteria of evaluation used in the European Organization for Research and Treatment of Cancer--Genitourinary Group Study 30853

1 reference

12 December 2020

High-dose bicalutamide monotherapy for the treatment of prostate cancer

1 reference

12 December 2020

Low-dose cyproterone acetate plus mini-dose diethylstilbestrol—A protocol for reversible medical castration

1 reference

12 December 2020

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

12 December 2020

Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer

1 reference

12 December 2020

Intermittent androgen suppression for prostate cancer: rationale and clinical experience

1 reference

12 December 2020

Identifiers

PMC publication ID

1229995

1 reference

30 July 2017

1 reference